Management of recurrent hepatitis C following liver transplantation

Area of Science:

• Hepatology
• Transplantation Immunology
• Virology

Background:

• Hepatitis C virus (HCV) is a leading cause of liver transplantation in the US.
• Recurrent HCV infection post-transplant significantly increases graft loss and mortality.
• Progressive fibrosis and cirrhosis affect up to 30% of HCV transplant recipients within 5 years.

Purpose of the Study:

• To review risk factors for HCV recurrence after liver transplantation.
• To discuss the impact of immunosuppression on HCV-associated allograft failure.
• To evaluate current and emerging therapies for managing recurrent HCV infection in transplant patients.

Main Methods:

• Literature review of studies on HCV recurrence post-liver transplant.
• Analysis of risk factors including recipient, donor, and viral characteristics.
• Evaluation of immunosuppressive therapies and their association with HCV progression.
• Assessment of antiviral treatments, including peginterferon alfa/ribavirin and direct-acting antivirals.

Main Results:

• Recipient, donor, and viral factors contribute to HCV disease progression.
• Certain immunosuppressive regimens (pulse corticosteroids, T-cell depletion) are linked to allograft failure.
• Sustained virologic response with peginterferon alfa/ribavirin improves survival but is limited by tolerability.
• Emerging therapies show promise for better management.

Conclusions:

• Effective management of recurrent HCV infection is crucial for long-term liver transplant success.
• Direct-acting antivirals and steroid-sparing immunosuppression represent promising advancements.
• Personalized treatment strategies are needed to optimize outcomes for transplant recipients with HCV.